The Fibrinolytic Status in XXXX .

@entity1 @entity82 @entity409 @entity9660 @entity3851 @entity927
UNASSIGNED: The liver is the main site of synthesis and/or clearance of proteins involved in fibrinolysis. Therefore, @entity409 , including @entity82 , leads to altered plasma levels of fibrinolytic proteins. Historical studies using in vitro clot lysis assays suggested that @entity1 with @entity409 had accelerated fibrinolysis. Subsequent studies measured levels of individual pro- and antifibrinolytic proteins and showed that levels of tissue-type plasminogen activator are elevated. Plasma levels of plasminogen activator inhibitor-1 may also be altered, which leads to a shift in balance in the fibrinolytic system. Despite the fact that a more recent study using a plasma clot lysis assay challenged the existence of @entity9660 , other recent studies detected @entity9660 in a considerable number of @entity1 with @entity82 . Therefore, it is now recognized that @entity9660 may occur in 30 to 50% of @entity1 with @entity3851 . A causal role of @entity9660 in bleeding is difficult to establish because also other concomitant changes in hemostasis occur. Treatment of @entity9660 consists of the use of fibrinolysis inhibitors, such as @entity927 . In this review we summarize current insights of the role of the liver in fibrinolysis, changes in fibrinolytic proteins, the potential clinical implications, and management of @entity9660 in @entity409 .
